Liver injury forces Pfizer to ABANDON obesity pill The medicine won’t be advanced into final stage of testing The company will instead invest in 'earlier-stage treatments' for obesity
Liver injury forces Pfizer to ABANDON obesity pill
The medicine won’t be advanced into final stage of testing
The company will instead invest in 'earlier-stage treatments' for obesity
